ATE141162T1 - Antineoplastische lösung und verfahren zur behandlung von neoplasmen - Google Patents

Antineoplastische lösung und verfahren zur behandlung von neoplasmen

Info

Publication number
ATE141162T1
ATE141162T1 AT90907638T AT90907638T ATE141162T1 AT E141162 T1 ATE141162 T1 AT E141162T1 AT 90907638 T AT90907638 T AT 90907638T AT 90907638 T AT90907638 T AT 90907638T AT E141162 T1 ATE141162 T1 AT E141162T1
Authority
AT
Austria
Prior art keywords
vehicle
agent
tumor
tissue
antineoplastic
Prior art date
Application number
AT90907638T
Other languages
English (en)
Inventor
Dennis D Pietronigro
Original Assignee
Dennis D Pietronigro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dennis D Pietronigro filed Critical Dennis D Pietronigro
Application granted granted Critical
Publication of ATE141162T1 publication Critical patent/ATE141162T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT90907638T 1989-05-09 1990-05-08 Antineoplastische lösung und verfahren zur behandlung von neoplasmen ATE141162T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/349,410 US5051257A (en) 1989-05-09 1989-05-09 Antineoplastic solution and method for treating neoplasms

Publications (1)

Publication Number Publication Date
ATE141162T1 true ATE141162T1 (de) 1996-08-15

Family

ID=23372285

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90907638T ATE141162T1 (de) 1989-05-09 1990-05-08 Antineoplastische lösung und verfahren zur behandlung von neoplasmen

Country Status (9)

Country Link
US (1) US5051257A (de)
EP (1) EP0471751B1 (de)
JP (1) JP3101702B2 (de)
AT (1) ATE141162T1 (de)
AU (1) AU640657B2 (de)
CA (1) CA2055493C (de)
DE (1) DE69028102T2 (de)
ES (1) ES2090131T3 (de)
WO (1) WO1990013289A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162115A (en) * 1989-05-09 1992-11-10 Pietronigro Dennis D Antineoplastic solution and method for treating neoplasms
US6229145B1 (en) 1992-01-22 2001-05-08 Pem Technologies, Inc. Dedicated apparatus and method emission mammography
US5519221A (en) * 1992-01-22 1996-05-21 Ansel M. Schwartz Dedicated apparatus and method for emission mammography
SE9202128D0 (sv) * 1992-07-09 1992-07-09 Astra Ab Precipitation of one or more active compounds in situ
EP0739210B1 (de) * 1993-12-29 2002-07-24 Matrix Pharmaceutical, Inc. Zusammensetzung für lokale freigabe von zytostatika
US6322815B1 (en) 1994-07-22 2001-11-27 W. Mark Saltzman Multipart drug delivery system
ES2191719T3 (es) * 1994-11-10 2003-09-16 Univ Kentucky Res Found Dispositivo implantable y recargable de descarga controlada para suministrar farmacos directamente a una parte interna del cuerpo.
US6774278B1 (en) * 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US6630168B1 (en) 1997-02-20 2003-10-07 Biomedicines, Inc. Gel delivery vehicles for anticellular proliferative agents
JP2001527051A (ja) * 1997-12-31 2001-12-25 ダイレクト・セラピューティクス，インコーポレイテッド 組織灌流方法
US6753005B1 (en) 1997-12-31 2004-06-22 Direct Therapeutics, Inc. Method for tissue perfusion
US20050255039A1 (en) * 1998-06-26 2005-11-17 Pro Surg, Inc., A California Corporation Gel injection treatment of breast, fibroids & endometrial ablation
SE9803482D0 (sv) 1998-10-13 1998-10-13 Anders Holmberg Ion exchange tumor targeting (IETT)
AU775806B2 (en) 1998-12-22 2004-08-19 Genentech Inc. Vascular endothelial cell growth factor antagonists and uses thereof
US6428785B1 (en) 1999-10-28 2002-08-06 Immunolytics Inc. Method and composition for treating prostate cancer
US7803149B2 (en) * 2002-07-12 2010-09-28 Cook Incorporated Coated medical device
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
DE10244847A1 (de) * 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
WO2007085026A2 (en) * 2006-01-20 2007-07-26 The Board Of Regents Of The University Of Texas System Compositions and methods for the direct therapy of tumors
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
US8815818B2 (en) 2008-07-18 2014-08-26 Rxi Pharmaceuticals Corporation Phagocytic cell delivery of RNAI
WO2010033246A1 (en) 2008-09-22 2010-03-25 Rxi Pharmaceuticals Corporation Rna interference in skin indications
WO2010036702A1 (en) * 2008-09-25 2010-04-01 Cephalon, Inc. Liquid formulations of bendamustine
WO2010078536A1 (en) 2009-01-05 2010-07-08 Rxi Pharmaceuticals Corporation Inhibition of pcsk9 through rnai
US9745574B2 (en) 2009-02-04 2017-08-29 Rxi Pharmaceuticals Corporation RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US8541748B2 (en) * 2009-06-29 2013-09-24 General Electric Company System and method for performing nuclear mammography imaging
EP2550000A4 (de) 2010-03-24 2014-03-26 Advirna Inc Selbstfreisetzende rnai-verbindungen von reduzierter grösse
US20130143872A1 (en) * 2010-06-04 2013-06-06 Nicole Stieger Injectable formulation of a reverse transcriptase inhibitor for the treatment cancer
US11279934B2 (en) 2014-04-28 2022-03-22 Phio Pharmaceuticals Corp. Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
KR102689262B1 (ko) 2014-09-05 2024-07-30 피오 파마슈티칼스 코프. Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
CN109563509B (zh) 2015-10-19 2022-08-09 菲奥医药公司 靶向长非编码rna的减小尺寸的自递送核酸化合物
BR112022025512A2 (pt) * 2020-06-15 2023-01-17 Kortuc Inc Sensibilizador para tratamento de câncer
US11459567B2 (en) 2020-06-24 2022-10-04 Patricia Virginia Elizalde Specific siRNA molecules, composition and use thereof for the treatment of triple negative breast cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4300557A (en) * 1980-01-07 1981-11-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for treating intraocular malignancies
US4558690A (en) * 1982-01-26 1985-12-17 University Of Scranton Method of administration of chemotherapy to tumors
DE3360633D1 (en) * 1982-02-12 1985-10-03 Unitika Ltd Anti-cancer device
DE3513938A1 (de) * 1985-04-18 1986-10-23 Merck Patent Gmbh, 6100 Darmstadt Cytostatikahaltiges pharmakadepot
ATE66609T1 (de) * 1986-07-11 1991-09-15 Asta Pharma Ag Loesungen von oxazaphosphorinen mit verbesserter stabilitaet und verfahren zu deren herstellung.
US4978332A (en) * 1987-09-28 1990-12-18 Matrix Pharmaceutical, Inc. Treatments employing vasoconstrictive substances in combination with cytotoxic agents for introduction into cellular lesion areas

Also Published As

Publication number Publication date
EP0471751A1 (de) 1992-02-26
AU5636090A (en) 1990-11-29
US5051257A (en) 1991-09-24
WO1990013289A1 (en) 1990-11-15
DE69028102T2 (de) 1997-01-23
CA2055493A1 (en) 1990-11-10
AU640657B2 (en) 1993-09-02
ES2090131T3 (es) 1996-10-16
JPH04506659A (ja) 1992-11-19
EP0471751B1 (de) 1996-08-14
EP0471751A4 (en) 1992-07-22
JP3101702B2 (ja) 2000-10-23
CA2055493C (en) 2001-04-17
DE69028102D1 (de) 1996-09-19

Similar Documents

Publication Publication Date Title
DE69028102D1 (de) Antineoplastische lösung und verfahren zur behandlung von neoplasmen
ID25622A (id) Proses untuk memproduksi formulasi arsenat trioksida dan metoda untuk mengobati kanker dengan menggunakan arsenat trioksida atau melarsoprol
NZ334190A (en) Method for improved selectivity in photo-activation of molecular agents
DE69127175D1 (de) Antisens-Oligonukleotide zur Behandlung von Krebs
SE8803087L (sv) Ett nytt saett foer behandling av erektil dysfunktion
ES2063912T3 (es) Composiciones inmunogenicas frente a peptidos de gastrina.
ATE282425T1 (de) Verfahren zur behandlung von endothelialen verletzungen
ATE194916T1 (de) Intraoperative, intravaskulare und endoskopische bestimmung und behandlung von verletzungen und tumoren
ATE60697T1 (de) Verfahren zur bekaempfung von pilzen.
ATE242635T1 (de) Squalamin in kombination mit anderen antikrebs- mittelen zur behandlung von tumoren
ES2160707T3 (es) Composiciones que comprenden agentes deteriorantes del adn y p53.
ATE279215T1 (de) Verfahren zur behandlung von organen und gewebe
AR005962A1 (es) Aparato y composicion para la limpieza de una superficie
DE69320646D1 (de) Verfahren zur behandlung von krebs durch kombinationstherapie mit 2&#39;-halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
DE50209139D1 (de) Zweikomponenten-Mittel mit zeitlichem pH-Gradienten und Verfahren zur Behandlung von Haaren
ATE218320T1 (de) Kombinationen von vasoaktiven stoffen mit fettsäuren zur verhütung von haarausfall
NO994330L (no) Metode for behandling av en tumor
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
DE69431064D1 (de) Nassbehandlung von leder und pelzen
ATE291918T1 (de) Kombinationstherapie zur behandlung von tumoren
ATE251462T1 (de) Verfahren zur behandlung von narbengewebe
ATE110961T1 (de) Behandlung von beatmungsabhängigkeit mit wachstumshormon.
DE3775278D1 (de) Topische methotrexatzubereitung zur behandlung hyperproliferativer epithelerkrankungen.
DE68908445D1 (de) Mittel zur behandlung von lebererkrankungen.
DE69733321D1 (de) Olanzapine zur behandlung von drogenmissbrauch

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee